Metformin Fights Gut Inflammation by Cutting a Key Metabolic Fuel for STAT3
Metformin reduces colitis by lowering acetyl-CoA levels, blocking STAT3 acetylation and downstream inflammatory signaling in the gut.
Summary
Researchers at Wuhan University have uncovered a novel mechanism explaining how metformin—best known as a diabetes drug—fights intestinal inflammation. Using DSS-induced colitis mouse models and human intestinal epithelial cells, they showed that metformin reduces levels of acetyl-CoA, a central metabolic molecule that fuels the acetylation (chemical modification) of the transcription factor STAT3. When STAT3 is acetylated, it becomes more active and drives inflammatory gene expression. By reducing acetyl-CoA, metformin blocks this acetylation step, dampening STAT3 activity, lowering pro-inflammatory cytokines, preventing cell death, and restoring the gut's protective barrier proteins. Intestine-specific STAT3 knockout mice confirmed that STAT3 is essential for metformin's anti-inflammatory action.
Detailed Summary
Ulcerative colitis (UC) is a chronic inflammatory bowel disease with rising global prevalence and limited treatment efficacy—fewer than half of patients achieve sustained remission with current therapies. This study aimed to uncover new molecular mechanisms behind metformin's known ability to reduce DSS-induced colitis, with a specific focus on the metabolite acetyl-CoA and its role in modifying the transcription factor STAT3.
The research team used a multi-pronged approach: acute colitis was induced in C57BL/6J mice with 3% dextran sulfate sodium (DSS) for 7 days, while metformin was administered intraperitoneally at 100 or 200 mg/kg. Intestine-specific STAT3 knockout mice (STAT3-ΔIEC) were generated by crossing STAT3-flox mice with Villin-Cre mice to isolate the role of epithelial STAT3. Additional pharmacological experiments used Ex527 (a SIRT1 deacetylase inhibitor), Colivelin TFA (a STAT3 activator), and sodium acetate supplementation to dissect the acetyl-CoA/STAT3 acetylation axis. Human intestinal epithelial NCM460 cells treated with LPS served as the in vitro model.
Metformin significantly reduced DSS-induced disease activity: it shortened colon shrinkage, lowered histological inflammation scores, suppressed pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) at both gene and protein levels, and decreased epithelial apoptosis markers (Bax, cleaved caspase-3) while restoring anti-apoptotic Bcl-2. Tight junction proteins critical to barrier integrity—ZO-1, E-cadherin, and Occludin—were restored by metformin treatment. Transmission electron microscopy confirmed improved mitochondrial and tight junction ultrastructure.
Mechanistically, DSS-induced colitis elevated intracellular acetyl-CoA levels, which in turn drove acetylation of STAT3 at lysine 685 (K685)—a modification that promotes STAT3 nuclear translocation, dimerization, and transcriptional activity independent of canonical Tyr705 phosphorylation. Metformin reversed this by reducing acetyl-CoA production, thereby blocking STAT3 K685 acetylation and its downstream inflammatory program. When acetate was supplemented to restore acetyl-CoA levels in metformin-treated mice, the drug's protective effects were substantially negated. Similarly, Ex527 (which inhibits SIRT1-mediated STAT3 deacetylation) blunted metformin's benefits, and overexpression of acetylation-resistant STAT3 mutants confirmed K685 as the critical site. In STAT3-ΔIEC mice, metformin's anti-inflammatory efficacy was markedly diminished, confirming that epithelial STAT3 is the primary target.
These findings establish a coherent pathway: metformin → reduced acetyl-CoA → reduced STAT3 K685 acetylation → suppressed STAT3 transcriptional activity → less inflammation and better barrier function. This represents a mechanistically distinct action from metformin's canonical AMPK activation and adds acetyl-CoA metabolism as a druggable node in UC. The study also raises the possibility that other acetyl-CoA-lowering strategies could be explored for IBD treatment.
Key Findings
- Metformin reduced DSS-induced colitis severity, pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), and epithelial apoptosis in mice.
- DSS colitis elevates intracellular acetyl-CoA; metformin lowers acetyl-CoA, blocking STAT3 acetylation at lysine K685.
- Restoring acetyl-CoA via acetate supplementation reversed metformin's protective effects, confirming the metabolic mechanism.
- Intestine-specific STAT3 knockout mice showed significantly blunted responses to metformin, confirming epithelial STAT3 as the key target.
- Metformin restored tight junction proteins (ZO-1, E-cadherin, Occludin) and gut barrier integrity via the acetyl-CoA/STAT3 axis.
Methodology
Acute colitis was induced in C57BL/6J and intestine-specific STAT3 knockout mice using 3% DSS for 7 days, with intraperitoneal metformin at 100 or 200 mg/kg. In vitro studies used LPS-stimulated human NCM460 intestinal epithelial cells; mechanistic dissection employed pharmacological tools (Ex527, Colivelin, ETC-1002), acetate supplementation, siRNA knockdown, and STAT3 K685 acetylation-resistant mutant overexpression.
Study Limitations
All animal experiments used male mice only, limiting generalizability across sexes. The study did not assess gut microbiome contributions to acetyl-CoA changes or test oral metformin dosing (versus intraperitoneal), which is the clinically relevant route. Long-term efficacy and effects on chronic colitis or colitis-associated cancer were not examined.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.